Live Breaking News & Updates on Mayo Clinic Enterprise Department Of Cardiovascular Medicine

Stay updated with breaking news from Mayo clinic enterprise department of cardiovascular medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A

Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
Cardiol Therapeutics Inc. (
a clinical-stage biotechnology company
focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management s Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company s profile on SEDAR at www.sedar.com and on the Company s website at www.cardiolrx.com.
David Elsley, President and Chief Executive Officer of Cardiol, commented: 2020 was a very exciting year for Cardiol Therapeutics. We made extraordinary progress in our research and clinical development programs, while significantly strengthening our financial position. We are particularly excited about the progress made across our research and development programs supporting the development of CardiolRx, our pharmaceutically produced extra- ....

United States , Guilherme Oliveira , Carsten Tsch , Weldon Smith , David Elsley , Matthias Friedrich , Wilson Tang , Trevor Burns , Andrew Hamer , Peter Liu , Arvind Bhimaraj , Barry Trachtenberg , Heart Failure Research , Data Safety Monitoring Committee , Cardiol Therapeutics Inc , Shoppers Drug Mart Inc , Department Of Cardiovascular Medicine , University Of Pittsburgh , University Of Ottawa Heart Institute , Leslie Cooper Co , Mcgill University Health Centre , York Stock Exchange , Company Phase , Mayo Clinic Enterprise Department Of Cardiovascular Medicine , Steering Committee , American College Of Cardiology ,

Cardiol Therapeutics Inc.: Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

Cardiol Therapeutics Inc.: Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company s Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Oakville, Ontario (Newsfile Corp. - December 15, 2020) - Cardiol Therapeutics Inc. (
TSX: CRDL) (
Cardiol or the
Company ), a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ( CVD ), announces that it has appointed contract research organization ( CRO ) Worldwide Clinical Trials ( Worldwide ), as the Company initiates it s Phase II/III trial in high-risk patients hospitalized with COVID-19 at clinical centers throughout the United States. The double-blind, placebo-controlled clinical trial is designed to investigate the efficacy and safety of CardiolRx, a pharmaceutically produced extra strength cannabidiol formulation, in 422 hospitalized COVID-19 patients with a prior ....

United States , Dennis Mcnamara , Trevor Burns , Kostenloser Wertpapierhandel , Leslie Cooper , David Elsley , Heart Failure Research , Steering Committee , Mayo Clinic Enterprise Department Of Cardiovascular Medicine , Company Annual Information Form , Cardiol Therapeutics Inc , Newsfile Corp , University Of Pittsburgh , Department Of Cardiovascular Medicine , Worldwide Clinical Trials , South America , Mayo Clinic Enterprise Department , Cardiovascular Medicine , B Type Natriuretic Peptide , North America , Cardiol Therapeutics , Investor Relations , Annual Information Form , ஒன்றுபட்டது மாநிலங்களில் , டென்னிஸ் மக்நமர , ட்ரெவர் தீக்காயங்கள் ,